YD Bio Ltd (YDES) News & EventsYDESYD Bio Ltd

YD Bio Enters Strategic Alliance Agreement with YC Biotech

YD Bio announced that its subsidiary YD Bio USA entered into a Master Strategic Alliance Agreement with YC Biotech on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration for YC Biotech's Contract Research Organization, CRO, clients in Asia. Under the terms of the Agreement, YD Bio USA will serve as YC Biotech's exclusive U.S. Agent and formal liaison with the FDA. In this role, YD Bio USA will manage official communications and correspondence with the FDA, represent sponsors in pre-IND and other formal regulatory meetings, provide high-level U.S. regulatory pathway strategies and positioning advice, and serve as compliance risk advisor. YD Bio USA will also coordinate FDA inspection readiness efforts to facilitate compliance with applicable U.S. regulatory requirements.

YD Bio Signs LOI to Acquire SSMC

YD Bio announced it has entered into a binding Letter of Intent, LOI, to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology, SSMC. The LoI, executed on January 20, 2026, signifies a definitive step towards integrating SSMC's advanced immunocell therapy capabilities into YD Bio Ltd's strategic portfolio, further solidifying the Company's strategic transformation from a portfolio of assets to an end-to-end biotechnology ecosystem. Under the terms of the LoI, YD Bio Ltd intends to acquire 100% of the equity interests of Safe Save Cell Holdings, an offshore holding company to be established through a SSMC's corporate restructuring that will result in the KY Company holding 100% of SSMC's shares, for a total consideration of NT$839,832,000, or US$26.87M